Stocktoria
HAEMONETICS CORP HAE
HAEMONETICS CORP (HAE) earns a Piotroski F-score of 7/9 (strong financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2026 revenue was $1.3B at a 7.3% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.81 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-06-26 | BTIG | Buy (reit) |
| 2026-06-17 | BTIG | Buy (reit) |
| 2026-06-15 | Mizuho | Outperform (main) |
| 2026-05-28 | Citigroup | Neutral (main) |
| 2026-05-22 | B of A Securities | Buy (up) |
| 2026-05-12 | Barrington Research | Outperform (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 7/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.231 |
| Retained earnings / assets | 0.117 |
| EBIT / assets | 0.065 |
| Equity / liabilities | 0.498 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| HAE | HAEMONETICS CORP | 7/9 | 2.85 | 36.1 | -2% |
| PEN | Penumbra Inc | 6/9 | 8.59 | 70.1 | +17.5% |
| MMSI | MERIT MEDICAL SYSTEMS INC | 7/9 | 4.93 | 33.3 | +11.8% |
| EMBC | Embecta Corp. | 6/9 | 1.99 | 2.2 | -3.8% |
| IART | INTEGRA LIFESCIENCES HOLDINGS CORP | 5/9 | 1.17 | — | +1.5% |
| TNDM | TANDEM DIABETES CARE INC | 3/9 | -3.04 | — | +7.9% |
| INSP | Inspire Medical Systems, Inc. | 6/9 | 9.88 | 9.1 | +13.6% |
About HAEMONETICS CORP
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. The company also offers treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, it provides hospital products comprising TEG 6s system, smallest cartridge-based viscoelastic analyzer that provides a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, the company offers Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries;vascular closure products comprise VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen; and transfusion management solutions. It sells its products through direct sales force and independent distributors. The company was founded in 1971 and is headquartered in Boston, Massachusetts.
FAQ
Is HAE financially healthy?
HAEMONETICS CORP's Piotroski F-score is 7/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does HAE pay a dividend?
No, HAEMONETICS CORP does not currently pay a dividend.
How profitable is HAE?
In FY2026, HAEMONETICS CORP had a net margin of 7.3% and a return on equity of 12.2%.
Is HAE overvalued or undervalued?
HAEMONETICS CORP trades at about 44.6× trailing earnings — below its 10-year norm (10-year range 19.0×–126.7×, median 60.3×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for HAE?
The average Wall-Street price target for HAEMONETICS CORP is $85.20, about 6.7% below the recent price, from 10 analysts (consensus: buy).
Is HAE a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on HAEMONETICS CORP: a Piotroski F-score of 7/9, an Altman Z″ in the safe zone, a P/E of about 36.1×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2026-03-28. Facts plus Stocktoria's own computed scores — not investment advice.